<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20100127003210N18</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-09-09</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Vancomycin as antibiotic lock technique in prevention of catheter associated infection in stem cell transplantation patientsV</public_title>
      <acronym></acronym>
      <scientific_title>Effect of Vancomycin as antibiotic lock technique in prevention of catheter associated infection in stem cell transplantation patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/36518</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Permuted Block Randomization
The randomization scheme consists of a sequence of blocks such that each block contains 10 number of intervention assignments in random order. The BMT ward of Taleghani Hospital consisted of two nursing station (S1 and S2). In one station (S1), heparin plus vancomycin lock will be performed and in the other station, heparin lock will be done on patients. Equal allocation wil be planned in a two-armed trial (S1 and S2) using a randomization scheme of permuted blocks. Investigator plans to enroll 10 subjects per month. Individuals in this group were randomly assigned to one the two aforementioned nursing stations.
 Randomization will be done to generate random sequences on the web (http://www.graphpad.com/quick calc /index.cfm).
Each patient will go to one of the station based on randomization sequence. Block will be done for 21 days from catheterization day. Allocation concealment randomization will done from a SNOSE method, and will be kept by the hospital pharamcist of the two stations, Blinding description: Patients will be unaware of their allocated group.</study_design>
      <phase>2-3</phase>
      <hc_freetext>catheter- related Blood stream infection (CRBSI).</hc_freetext>
      <i_freetext>Intervention 1: Intervention group (5 mg vancomycin, 2500 IU/ml heparin): Every night at a certain time, patients in the intervention group receive the block solution (vacomycin-heparin) . This block is done for each patient in a 21- day time interval from the day of catheterization. The block time is at least 8 hours but depending on catheter availability it may increase. When dwell time is over,  researcher aspirates antibiotic lock solution from catheter lumen, flush catheter with 5ml normal saline before using line to administer medication.This process is done by the trained nurse. Lock solution is prepared based on it’s stability every 72 hour by pharmacist. Solution vancomycin-heparin stable 72 hours in room temperature based on Antibiotic Lock solution Therapy Guideline. Intervention 2: Control group (Heparin only 100IU/ml base on routine program in ward): This block is done for each patient in a 21-day time range started at the day of catheterization. The block time will be at least 8 hours and depending on availability catheter may increase.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is secret</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maria Tavakoli Ardakani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Clinical Pharmacy School of Pharmacy Shahid Beheshti University of Medical of Sciences Theran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>14155-6153</zip>
        <telephone>+98 21 8820 0085</telephone>
        <email>mariatavakoli@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Maria Tavkoli Ardakani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Beheshti University of Medical Sciences Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>14155-6153</zip>
        <telephone>+98 21 8820 0085</telephone>
        <email>mariatavakoli@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All of patients undergoing HSCT whom non-tunneled CVC (arrow) will be inserted newly.</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Hypersensivity to Vancomycin</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>B95</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Streptococcus, Staphylococcus, and Enterococcus as the cause of diseases classified elsewhere</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group (5 mg vancomycin, 2500 IU/ml heparin): Every night at a certain time, patients in the intervention group receive the block solution (vacomycin-heparin) . This block is done for each patient in a 21- day time interval from the day of catheterization. The block time is at least 8 hours but depending on catheter availability it may increase. When dwell time is over,  researcher aspirates antibiotic lock solution from catheter lumen, flush catheter with 5ml normal saline before using line to administer medication.This process is done by the trained nurse. Lock solution is prepared based on it’s stability every 72 hour by pharmacist. Solution vancomycin-heparin stable 72 hours in room temperature based on Antibiotic Lock solution Therapy Guideline.</i_keyword>
      <i_keyword>Control group (Heparin only 100IU/ml base on routine program in ward): This block is done for each patient in a 21-day time range started at the day of catheterization. The block time will be at least 8 hours and depending on availability catheter may increase</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Fever, erythema, purulence (catheter exit site), swelling. Timepoint: observe for 21 days from catheterization. Method of measurement: clinical examination, thermometer.</prim_outcome>
      <prim_outcome>Infection. Timepoint: observe for 21 days from catheterization. Method of measurement: Blood culture (peripheral, catheter).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>WBC and Platelet engraftment. Timepoint: start of antibiotic lock until 21 days after. Method of measurement: CBC.</sec_outcome>
      <sec_outcome>Hospitalization time. Timepoint: from day of antibiotic lock until hospital clearance. Method of measurement: Day count.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-02-19</approval_date>
        <contact_name>Ethics committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>Department of Clinical Pharmacy, School of Pharmacy Shahid Beheshti University of Medical Sciences Tehran, IRAN Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
